Icade Framtida tillväxt
Future kriterier kontrolleras 3/6
Icade förväntas öka intäkter och intäkter med 86.7% respektive 1.6% per år. EPS förväntas tillväxt med 94.6% per år. Avkastningen på eget kapital förväntas bli 5.6% om 3 år.
Viktig information
86.7%
Tillväxttakt i vinsten
94.65%
Tillväxttakt för EPS
| REITs vinsttillväxt | 12.1% |
| Intäkternas tillväxttakt | 1.6% |
| Framtida avkastning på eget kapital | 5.60% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 06 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • May 22
ICAD: Slower Healthcare Exit And Paused Special Payouts Will Shape Balanced Outlook
Analysts have nudged their fair value estimate for Icade slightly lower to about €21.31. This reflects a reduced price target and updated assumptions around slower revenue growth, a modestly softer profit margin, a higher discount rate and the view that asset disposals and potential special dividends may take longer to materialise.
Uppdatering av berättelse • May 06
ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.Uppdatering av berättelse • Apr 21
ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.Uppdatering av berättelse • Apr 06
ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
Uppdatering av berättelse • Mar 23
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.Uppdatering av berättelse • Mar 08
ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.Uppdatering av berättelse • Feb 22
ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.Uppdatering av berättelse • Feb 08
ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.Uppdatering av berättelse • Jan 24
ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.Uppdatering av berättelse • Jan 10
ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.Uppdatering av berättelse • Dec 26
ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.Uppdatering av berättelse • Dec 12
ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Ny berättelse • Apr 28
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.Analysartikel • Feb 23
A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...Analysartikel • Jan 19
How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Analysartikel • Dec 13
What Type Of Shareholders Make Up Icade SA's (EPA:ICAD) Share Registry?
If you want to know who really controls Icade SA ( EPA:ICAD ), then you'll have to look at the makeup of its share...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 1,409 | 244 | 111 | 181 | 4 |
| 12/31/2027 | 1,328 | 154 | 831 | 208 | 5 |
| 12/31/2026 | 1,304 | 47 | 962 | 253 | 5 |
| 12/31/2025 | 1,337 | -123 | 300 | 300 | N/A |
| 9/30/2025 | 1,338 | -155 | 314 | 314 | N/A |
| 6/30/2025 | 1,339 | -187 | 328 | 328 | N/A |
| 3/31/2025 | 1,376 | -231 | 347 | 347 | N/A |
| 12/31/2024 | 1,412 | -275 | 366 | 366 | N/A |
| 9/30/2024 | 1,468 | -614 | 316 | 316 | N/A |
| 6/30/2024 | 1,523 | -953 | 265 | 265 | N/A |
| 3/31/2024 | 1,524 | -1,121 | 251 | 251 | N/A |
| 12/31/2023 | 1,525 | -1,289 | 238 | 238 | N/A |
| 9/30/2023 | 1,494 | -1,116 | 317 | 317 | N/A |
| 6/30/2023 | 1,464 | -944 | 397 | 397 | N/A |
| 3/31/2023 | 1,467 | -657 | 319 | 319 | N/A |
| 12/31/2022 | 1,469 | -370 | 242 | 242 | N/A |
| 9/30/2022 | 1,496 | -61 | N/A | N/A | N/A |
| 6/30/2022 | 1,524 | 249 | 547 | 224 | N/A |
| 3/31/2022 | 1,586 | 324 | 538 | 377 | N/A |
| 12/31/2021 | 1,648 | 399 | 529 | 529 | N/A |
| 6/30/2021 | 1,640 | 280 | -51 | 600 | N/A |
| 3/31/2021 | 1,534 | 178 | 34 | 625 | N/A |
| 12/31/2020 | 1,429 | 76 | 120 | 650 | N/A |
| 6/30/2020 | 1,458 | 259 | -233 | 453 | N/A |
| 3/31/2020 | 1,485 | 278 | -325 | 411 | N/A |
| 12/31/2019 | 1,512 | 298 | -417 | 369 | N/A |
| 9/30/2019 | 1,587 | 235 | N/A | 358 | N/A |
| 6/30/2019 | 1,662 | 173 | N/A | 346 | N/A |
| 3/31/2019 | 1,717 | 165 | N/A | 351 | N/A |
| 12/31/2018 | 1,773 | 156 | N/A | 356 | N/A |
| 9/30/2018 | 1,714 | 137 | N/A | 372 | N/A |
| 6/30/2018 | 1,655 | 118 | N/A | 387 | N/A |
| 3/31/2018 | 1,642 | 142 | N/A | 362 | N/A |
| 12/31/2017 | 1,629 | 165 | N/A | 337 | N/A |
| 6/30/2017 | 1,596 | 106 | N/A | 255 | N/A |
| 3/31/2017 | 1,542 | 75 | N/A | 235 | N/A |
| 12/31/2016 | 1,487 | 45 | N/A | 215 | N/A |
| 6/30/2016 | 1,391 | -101 | N/A | 309 | N/A |
| 3/31/2016 | 1,411 | -144 | N/A | 307 | N/A |
| 12/31/2015 | 1,431 | -187 | N/A | 305 | N/A |
| 6/30/2015 | 1,649 | 82 | N/A | 526 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: ICAD förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 2.5% ).
Resultat vs marknad: ICAD förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.
Höga tillväxtresultat: ICAD förväntas bli lönsam under de kommande 3 åren.
Intäkt vs marknad: ICAD s intäkter ( 1.6% per år) förväntas växa långsammare än marknaden för French ( 5.7% per år).
Hög tillväxtintäkter: ICAD s intäkter ( 1.6% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: ICAD s avkastning på eget kapital förväntas bli låg om 3 år ( 5.6 %).
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/27 05:14 |
| Aktiekurs vid dagens slut | 2026/05/27 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Icade bevakas av 21 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Celine Huynh | Barclays |